Telescope Innovations Corp (TSE:TELI) has released an update.
Telescope Innovations Corp reported a revenue of $686,205 in the second fiscal quarter of 2024, underpinned by robust sales of its flagship product DirectInject-LC™ and marked by new partnerships and global distribution agreements. The company also strengthened its executive team with seasoned industry professionals and filed provisional patents, enhancing its R&D and commercialization capabilities. Despite these positive developments, the company’s expenses outstripped revenues, signaling aggressive investment in growth.
For further insights into TSE:TELI stock, check out TipRanks’ Stock Analysis page.
